Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Celsion, Zhejiang Hisun sign deal to develop GEN-1 immuno-oncology therapy Celsion has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement with Zhejiang Hisun Pharmaceutical to pursue an expanded partnership for the technology transfer relating to the clinical and commercial manufacture and supply of GEN-1, Celsion's gene mediated, IL-12 immunotherapy, for the greater China territory, with the option to expand into other countries in the rest of the world after all necessary regulatory approvals are in effect.
Contract Research & Services > Contract Services > News
Juno Therapeutics forms multiple myeloma partnership with MSK and Eureka Therapeutics Juno Therapeutics has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma.
Contract Research & Services > Contract Services > News Amgen secures rights to Advaxis’ cancer immunotherapy treatment By PBR Staff Writer
Amgen has acquired global rights to a preclinical cancer immunotherapy treatment developed by Advaxis.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Merck to offer Provantage end-to-end development and manufacturing services to Y-mAbs
Merck will provide its Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of Y-mAbs' monoclonal antibody in late stage clinical development.
Contract Research & Services > Contract Services > News
Orexigen signs commercialization deal with Laboratorios Farmace´utico for Mysimba in Spain
Orexigen Therapeutics' wholly owned subsidiary Orexigen Therapeutics Ireland and Laboratorios Farmacéuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Spain.
Contract Research & Services > Contract Services > News
Profil Institute, HighTide Biopharmaceutical partner to develop new therapies for diabetes and NAFLD/NASH
Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, announced today a strategic master services agreement with Shenzhen HighTide Biopharmaceutical, a subsidiary of Shenzhen Hepalink Pharmaceutical.
Contract Research & Services > Contract Services > News
Almirall, Sun Pharma sign license deal to develop tildrakizumab for psoriasis in Europe
Sun Pharma, Sun Pharmaceutical Industries and its subsidiaries or associate companies, and Almirall have signed a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe.
Contract Research & Services > Contract Services > News
Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate
Kite Pharma has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies.
Contract Research & Services > Contract Services > News
Trek Therapeutics acquires two antiviral inhibitors from Vertex Pharmaceuticals
Trek Therapeutics has acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir (VX-222), a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib (VX-497), an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests